EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

Shu Chen Wei, Hiroshi Nakase iD, Byong Duk Ye, Kang Chao iD, Hsin-Yun Wu, Jason Eccleston, Xuan Yao, Hannah Palac, Mohamed-Eslam F Mohamed iD, Ana Victoria Ponce-Bobadilla, Smitha Suravaram, Elena Marced Barrachina und 2 weitere

Journal of Gastroenterology and Hepatology · 2026

DOI: 10.1111/jgh.70634 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Shu Chen Wei und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Inc., AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Upadacitinib, a selective Janus kinase 1 inhibitor, is approved to treat moderately to severely active ulcerative colitis (UC). This post hoc subanalysis evaluated the efficacy, safety, and pharmacokinetics of upadacitinib in patients in East Asia.

Methods

U‐ACHIEVE (UC1; NCT02819635) and U‐ACCOMPLISH (UC2; NCT03653026) were Phase 3, multicenter, randomized, double‐blind, induction studies evaluating upadacitinib 45 mg or placebo daily in adults with moderately to severely active UC. Clinical responders to 8 weeks of upadacitinib induction were eligible to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo daily in the 52‐week U‐ACHIEVE maintenance study (UC3; NCT02819635). Efficacy outcomes, safety, and pharmacokinetics were evaluated among East Asian patients.

Results

A higher proportion of East Asian patients achieved clinical remission with upadacitinib than placebo at induction Week 8 (UC1: n = 127, 31.4% vs. 7.3%; UC2: n = 114, 31.2% vs. 2.7%) and maintenance Week 52 (UC3: n = 184, upadacitinib 15 mg, 52.4%; upadacitinib 30 mg, 53.8%; placebo, 10.7%). Rates of endoscopic outcomes were higher with upadacitinib than with placebo across studies. No new safety signals were identified. Herpes zoster occurrences were low (UC1 and UC2: upadacitinib 45 mg, two events [in one patient]; placebo, zero events; UC3: upadacitinib 15 mg, five events; upadacitinib 30 mg, eight events; placebo, zero events). Pharmacokinetics and trends in the relationship between upadacitinib exposure and efficacy were consistent in the East Asian and global populations.

Conclusion

Upadacitinib was generally well tolerated and effective for treating moderately to severely active UC in patients in East Asia, with a favorable benefit–risk profile consistent with the global population. Trial Registration: ClinicalTrials.gov identifier: NCT02819635, NCT03653026

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsHumansMaleAdultTreatment OutcomeDouble-Blind MethodFemaleSeverity of Illness IndexMiddle AgedAsia, EasternJanus Kinase 1Remission Induction

Stichwörter der Autor:innen

East Asian peopleJanus kinase inhibitorspharmacokineticstreatment outcomeulcerative colitis

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingJanus Kinase 1Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
  • Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Internal Medicine, National Taiwan University Hospital Jinshan Branch, New Taipei City, Taiwan.
  • AbbVie Inc., North Chicago, Illinois, USA.

ORCID-Profile: Hiroshi Nakase, Kang Chao, Mohamed-Eslam F Mohamed

Förderung

  • AbbVie Inc.
  • AbbVie

Zitieren

APA

Wei, S. C., Nakase, H., Ye, B. D., Chao, K., Wu, H. Y., Eccleston, J., Yao, X., Palac, H., Mohamed, M. F., Ponce-Bobadilla, A. V., Suravaram, S., Barrachina, E. M., Hisamatsu, T., & Gao, X. (2026). Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70634

Vancouver

Wei SC, Nakase H, Ye BD, Chao K, Wu HY, Eccleston J, et al. Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70634

BibTeX
@article{Wei2026,
  author = {Wei, Shu Chen and Nakase, Hiroshi and Ye, Byong Duk and Chao, Kang and Wu, Hsin-Yun and Eccleston, Jason and Yao, Xuan and Palac, Hannah and Mohamed, Mohamed-Eslam F and Ponce-Bobadilla, Ana Victoria and Suravaram, Smitha and Barrachina, Elena Marced and Hisamatsu, Tadakazu and Gao, Xiang},
  title = {Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1111/jgh.70634}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche